These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 16639484)
1. [A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens]. Cuomo G; Molinaro G; La Montagna G; Migliaresi S; Valentini G Reumatismo; 2006; 58(1):22-5. PubMed ID: 16639484 [TBL] [Abstract][Full Text] [Related]
2. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591 [TBL] [Abstract][Full Text] [Related]
3. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure. Wakabayashi H; Hasegawa M; Nishioka Y; Minami Y; Nishioka K; Sudo A Clin Rheumatol; 2013 Feb; 32(2):253-9. PubMed ID: 23179002 [TBL] [Abstract][Full Text] [Related]
4. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Smolen JS; Breedveld FC; Schiff MH; Kalden JR; Emery P; Eberl G; van Riel PL; Tugwell P Rheumatology (Oxford); 2003 Feb; 42(2):244-57. PubMed ID: 12595618 [TBL] [Abstract][Full Text] [Related]
5. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Aletaha D; Funovits J; Keystone EC; Smolen JS Arthritis Rheum; 2007 Oct; 56(10):3226-35. PubMed ID: 17907167 [TBL] [Abstract][Full Text] [Related]
6. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Tang B; Rahman M; Waters HC; Callegari P Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998 [TBL] [Abstract][Full Text] [Related]
7. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate. Kaeley GS; Nishio MJ; Goyal JR; MacCarter DK; Wells AF; Chen S; Kupper H; Kalabic J Arthritis Rheumatol; 2016 Nov; 68(11):2584-2592. PubMed ID: 27214046 [TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040 [TBL] [Abstract][Full Text] [Related]
9. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474 [TBL] [Abstract][Full Text] [Related]
10. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762 [TBL] [Abstract][Full Text] [Related]
11. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M; Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405 [TBL] [Abstract][Full Text] [Related]
12. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Jani M; Chinoy H; Warren RB; Griffiths CE; Plant D; Fu B; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Barton A; Arthritis Rheumatol; 2015 May; 67(8):2011-9. PubMed ID: 26109489 [TBL] [Abstract][Full Text] [Related]
13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU; Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810 [TBL] [Abstract][Full Text] [Related]
14. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661 [TBL] [Abstract][Full Text] [Related]
15. Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study. Mandl P; Balint PV; Brault Y; Backhaus M; D'Agostino MA; Grassi W; van der Heijde D; de Miguel E; Wakefield RJ; Logeart I; Dougados M Arthritis Care Res (Hoboken); 2013 Jun; 65(6):879-87. PubMed ID: 23213004 [TBL] [Abstract][Full Text] [Related]
16. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents. Ikeda K; Nakagomi D; Sanayama Y; Yamagata M; Okubo A; Iwamoto T; Kawashima H; Takahashi K; Nakajima H J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096 [TBL] [Abstract][Full Text] [Related]
17. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis. Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Symmons DP; Watson KD; Silman AJ; Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520 [TBL] [Abstract][Full Text] [Related]
19. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182 [TBL] [Abstract][Full Text] [Related]
20. Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study. Wakabayashi H; Hasegawa M; Nishioka Y; Sudo A; Nishioka K Mod Rheumatol; 2012 Feb; 22(1):116-21. PubMed ID: 21710357 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]